Researchers have found that a cancer-fighting virus called VSV kills the most malignant form of brain cancer in mice, targeting invasive tumour cells. The study also discovered that delivering VSV intravenously can effectively treat malignant glioma with minimal side effects.
The new technology allows for standardized, electronic reports after surgeries, improving data analysis and patient outcomes. It has been adopted by the Alberta Cancer Board and other health regions, tracking surgical effectiveness and resource allocation.
A randomized trial involving 250 patients with advanced prostate cancer found that high-dose calcitriol (DN-101) significantly reduced venous and arterial thromboses compared to a placebo. This unexpected benefit offers an avenue of investigation for improved safety in various cancers.
A new professorship in melanoma research has been established at the Cross Cancer Institute in Edmonton, Alberta. The endowment fund, valued at $1 million, will support long-term commitment to researching key pathways in melanoma development that could lead to potential targets for prevention and therapy.